Cyteir’s $133.2 Million Initial Public Offering

Davis Polk advised the representatives of the several underwriters in the IPO.

Cyteir Therapeutics, Inc. executed the $133.2 million initial public offering of 7,400,000 shares of common stock of its common stock is listed on the Nasdaq Global Select Market under the symbol “CYT.”

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and BofA Securities, Inc. acted as joint book-running managers of the offering and as representatives of the underwriters.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick (Picture) and Yasin Keshvargar and associates Moses Farzan Nekou, Christian Knoble and Gil Savir. Counsel Kiara L. Rankin provided tax advice. Partner David R. Bauer and associates Christopher C. Woller and Marisa Elena Bannon provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. 

Involved fees earner: Marisa Elena Bannon – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Moses Farzan Nekou – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Christian Knoble – Davis Polk & Wardwell; Kiara Rankin – Davis Polk & Wardwell; Gil Savir – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Bank of America Securities; J.P. Morgan Securities LLC; Morgan Stanley;

Author: Martina Bellini